$PTIXW News
Last published 4y ago
- 4y agoPTIXPTIXWProtagenic Therapeutics Announces Third Quarter 2021 Results and Business UpdateGlobeNewswireNEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the third quarter ended Septem
- 5y agoPTIXPTIXWProtagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ETGlobeNewswireScientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company f
- 5y agoPTIXPTIXWProtagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business UpdateGlobeNewswireNEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June
- 5y agoPTIXPTIXWProtagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical TrialGlobeNewswireNEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that upon reviewing its investigational ne
- 5y agoPTIXPTIXWProtagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ETGlobeNewswireNEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KO
- 5y agoPTIXPTIXWProtagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to NasdaqGlobeNewswireNew York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a public offering price of $4.15 per unit. Each unit is